Abstract
A prospective study was conducted to test the hypothesis that cocaine use is a risk factor for neuroleptic-induced acute dystonia (NIAD). The study sample consisted of a high-risk group for NIAD, males aged 17-45 years who had received high-potency neuroleptics within 24 hours of admission and had not used neuroleptics in the month prior to admission. Patients were excluded if they suffered from a neurodegenerative disorder or were exposed to anticholinergics, benzodiazepines, promethazine, carbamazepine, phenytoin, or levodopa during the study. Twenty-nine patients--9 cocaine users and 20 nonusers--entered the study, which lasted 2 years. Patients were followed for 7 days. Cocaine-using psychiatric patients developed significantly more NIAD than did nonusers (relative risk = 4.4, 95% CI = 1.4 to 13.9). Cocaine use is a major risk factor for NIAD and should be added to the list of well-known risk factors. The authors strongly suggest that cocaine-using psychiatric patients who are started on a regimen of neuroleptics should also be administered an anticholinergic for at least 7 days to prevent NIAD.
Citations
Jun 30, 2005·Journal of Psychiatric Practice·Michael H AllenRuth Ross
Dec 18, 2007·Psychiatry and Clinical Neurosciences·Nobutomo YamamotoToshiya Inada
Sep 3, 1999·BMJ : British Medical Journal·P N van HartenR S Kahn
May 18, 2006·Journal of Neurology, Neurosurgery, and Psychiatry·S PotvinE Stip
Nov 30, 2014·Neurologic Clinics·Shyamal H MehtaKapil D Sethi
Jan 12, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·David J VinkersPeter N van Harten
May 9, 2007·General Hospital Psychiatry·Harpreet S Duggal
Mar 9, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Harpreet Singh Duggal
Apr 3, 2012·The Anatomical Record : Advances in Integrative Anatomy and Evolutionary Biology·Haifeng HouHong Zhang
Jul 30, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Simon ZhornitskyStéphane Potvin
Mar 28, 2013·Human Psychopharmacology·Lars K HansenDavid Kingdon
Oct 7, 2004·Neuropharmacology·Nora D VolkowGene-Jack Wang
Jul 23, 2004·Expert Opinion on Drug Safety·John H ShaleWilliam D Mastin
Jul 18, 2009·Schizophrenia Research·Stéphane PotvinEmmanuel Stip
Apr 21, 2004·Molecular Psychiatry·N D VolkowJ M Swanson
Oct 28, 2019·Medicine·Ruili ZhangJinwen Huang
Sep 10, 2020·Journal of Psychopharmacology·Anton Jm Loonen, Svetlana A Ivanova
Dec 2, 2005·Journal of Psychiatric Practice·Michael H AllenUNKNOWN Expert Consensus Panel for Behavioral Emergencies 2005
Apr 24, 2010·CNS Spectrums·Icro MaremmaniHagop Akiskal
Aug 22, 2018·Der Nervenarzt·D HirjakR C Wolf